2型糖尿病中的肠促胰岛素：除降糖作用外的心血管和抗动脉粥样硬化作用
Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.
作者信息
Psallas M, Manes C
机构信息
Diabetic Center, Papageorgiou Teaching Hospital, Thessaloniki, Greece.
出版信息
Hippokratia. 2012 Apr;16(2):100-5.
Abstract
Type 2 diabetes mellitus is the most outspreading disease of the western world and it provides cardiovascular disease. During the past decade new drug categories were added to the already existing ones. Perhaps, the most outstanding, as promising, too, are glucagon-like peptide-1(GLP-1) analogues, which pinpointed at the incretin hormone system, targeting mainly at the postprandial hyperglycemia.It seemed that these novel drugs have beneficial effects on ischemic heart, heart failure,blood pressure, even on lipids and body weight in type 2 diabetics, considering them not only as another glucose lowering agent. A lot of recent studies investigate the potential relationship between GLP-1 and its possible cardioprotective and anti-atherogenic effects in type 2 diabetes and the present review discusses these effects of GLP-1.
摘要
2型糖尿病是西方世界传播最广的疾病，它会引发心血管疾病。在过去十年里，在已有的药物种类中又增加了新的类别。也许，最突出且同样有前景的是胰高血糖素样肽-1（GLP-1）类似物，它针对肠促胰岛素激素系统，主要针对餐后高血糖。似乎这些新型药物对2型糖尿病患者的缺血性心脏、心力衰竭、血压，甚至对血脂和体重都有有益影响，因此不仅将它们视为另一种降糖药物。最近许多研究探讨了GLP-1与2型糖尿病中其可能的心脏保护和抗动脉粥样硬化作用之间的潜在关系，本综述讨论了GLP-1的这些作用。
相似文献
1
Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.2型糖尿病中的肠促胰岛素：除降糖作用外的心血管和抗动脉粥样硬化作用
Hippokratia. 2012 Apr;16(2):100-5.
2
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.基于肠促胰岛素的疗法的降糖及抗动脉粥样硬化作用：胰高血糖素样肽-1类似物和二肽基肽酶-4抑制剂。
Expert Opin Investig Drugs. 2009 Oct;18(10):1495-503. doi: 10.1517/14728220903241633.
3
Blood pressure-lowering effects of incretin-based diabetes therapies.基于肠促胰岛素的糖尿病治疗药物的降压作用。
Can J Diabetes. 2014 Oct;38(5):364-71. doi: 10.1016/j.jcjd.2014.05.001.
4
Cardiovascular biology of the incretin system.肠促胰岛素系统的心血管生物学。
Endocr Rev. 2012 Apr;33(2):187-215. doi: 10.1210/er.2011-1052. Epub 2012 Feb 8.
5
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.新型降糖药物与二甲双胍联合治疗 2 型糖尿病的心血管疗效的性别差异。
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. doi: 10.1161/JAHA.119.012940. Epub 2020 Jan 4.
6
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.基于双重肠促胰岛素受体激活的糖尿病和肥胖治疗：“双激素”。
Diabetes Obes Metab. 2016 Sep;18(9):847-54. doi: 10.1111/dom.12685. Epub 2016 Jun 7.
7
Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.超越降糖作用：胰高血糖素样肽-1 受体激动剂、体重与心血管系统。
Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25.
8
Understanding the cardiovascular effects of incretin.了解肠促胰岛素的心血管作用。
Diabetes Metab J. 2011 Oct;35(5):437-43. doi: 10.4093/dmj.2011.35.5.437. Epub 2011 Oct 31.
9
Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.基于肠促胰岛素的治疗的胰腺外作用：在 2 型糖尿病患者的心血管风险管理中的潜在获益。
Diabetes Obes Metab. 2013 Jul;15(7):593-606. doi: 10.1111/dom.12050. Epub 2013 Jan 21.
10
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
引用本文的文献
1
Benefits of Whey Proteins on Type 2 Diabetes Mellitus Parameters and Prevention of Cardiovascular Diseases.乳清蛋白对 2 型糖尿病参数的益处及对心血管疾病的预防作用。
Nutrients. 2023 Mar 6;15(5):1294. doi: 10.3390/nu15051294.
2
The Evaluation of Dipeptidyl Peptidase (DPP)-IV, α-Glucosidase and Angiotensin Converting Enzyme (ACE) Inhibitory Activities of Whey Proteins Hydrolyzed with Serine Protease Isolated from Asian Pumpkin ().从亚洲南瓜中分离的丝氨酸蛋白酶水解乳清蛋白的二肽基肽酶（DPP）-IV、α-葡萄糖苷酶和血管紧张素转换酶（ACE）抑制活性的评估
Int J Pept Res Ther. 2014;20(4):483-491. doi: 10.1007/s10989-014-9413-0. Epub 2014 Jun 1.
本文引用的文献
1
Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes.高血糖与血管壁：糖尿病患者动脉粥样硬化负担的病理生理学方面
Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S15-9. doi: 10.1097/01.hjr.0000368193.24732.66.
2
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.二甲双胍对 2 型糖尿病患者心率和血压的影响：一项双盲、安慰剂对照、随机先导研究。
Cardiovasc Diabetol. 2010 Jan 28;9:6. doi: 10.1186/1475-2840-9-6.
3
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.基于肠促胰岛素的疗法的降糖及抗动脉粥样硬化作用：胰高血糖素样肽-1类似物和二肽基肽酶-4抑制剂。
Expert Opin Investig Drugs. 2009 Oct;18(10):1495-503. doi: 10.1517/14728220903241633.
4
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.长期输注胰高血糖素样肽-1可维持自发性高血压、易发生心力衰竭大鼠的左心室收缩功能并延长其生存期。
Circ Heart Fail. 2008 Sep;1(3):153-60. doi: 10.1161/CIRCHEARTFAILURE.108.766402.
5
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.利拉鲁肽与甘精胰岛素及安慰剂联合二甲双胍和磺脲类药物治疗2型糖尿病（LEAD-5 met+SU）：一项随机对照试验
Diabetologia. 2009 Oct;52(10):2046-55. doi: 10.1007/s00125-009-1472-y. Epub 2009 Aug 14.
6
Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.在封闭胸腔猪缺血再灌注模型中，皮下注射及缺血前给予利拉鲁肽均未产生心脏保护作用。
BMC Cardiovasc Disord. 2009 Jul 23;9:31. doi: 10.1186/1471-2261-9-31.
7
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).利拉鲁肽每日一次与艾塞那肽每日两次治疗2型糖尿病的比较：一项为期26周的随机、平行组、多国、开放标签试验（LEAD-6）
Lancet. 2009 Jul 4;374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0. Epub 2009 Jun 8.
8
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).利拉鲁肽，一种每日一次的人胰高血糖素样肽-1类似物，在26周内添加到磺脲类药物中，与在2型糖尿病患者中添加罗格列酮或安慰剂相比，在血糖和体重控制方面产生了更大的改善（LEAD-1 SU）。
Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.
9
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).人胰高血糖素样肽-1类似物利拉鲁肽联合二甲双胍和噻唑烷二酮治疗2型糖尿病患者的疗效和安全性（LEAD-4 Met+TZD研究）
Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16.
10
Glucose normalization and outcomes in patients with acute myocardial infarction.急性心肌梗死患者的血糖正常化与预后
Arch Intern Med. 2009 Mar 9;169(5):438-46. doi: 10.1001/archinternmed.2008.593.
Zotero 插件